Press & Publications


Accure Therapeutics presented at ECTRIMS four communications reporting the progress of ACT-01 neuroprotective therapy for Multiple Sclerosis

Press release

Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01


New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis